| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1369722 | Bioorganic & Medicinal Chemistry Letters | 2016 | 10 Pages |
The design and construction of a series of novel aminothiazole-derived γ-secretase modulators is described. The incorporation of heterocyclic replacements of the terminal phenyl D-ring of lead compound 1 was conducted in order to align potency with favorable drug-like properties. γ-Secretase modulator 28 displayed good activity for in vitro inhibition of Aβ42, as well as substantial improvement in ADME and physicochemical properties, including aqueous solubility. Pharmacokinetic evaluation of compound 28 in mice revealed good brain penetration, as well as good clearance, half-life, and volume of distribution which collectively support the continued development of this class of compounds.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
